Demonstrated successful Proof of Mechanism human trial with first clinical development compound.
Completed license-option agreement with Bayer Schering Pharma for PET amyloid imaging compound.
Secured collaborations with four pharmaceutical partners, including several top tier global pharma companies.
Raised $9M in Series A/B financing
Assembled world class development team and established a state-of-the-art R&D lab.
Developed robust pipeline of clinical development compounds from technology in-licensed from the University of Pennsylvania and the University of Michigan.
Raised $26M in Series C financing.
Selected and advanced development compounds into Phase II clinical trials for imaging β-amyloid and VMAT2 in Alzheimer's disease, Parkinson's disease, Dementia with Lewy Bodies, as well as early stage clinical studies in Diabetes.
Established strong IP position in support of pipeline programs.
